Rice Hall James & Associates LLC Has $7.05 Million Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Rice Hall James & Associates LLC decreased its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 1.7% during the 4th quarter, HoldingsChannel reports. The fund owned 411,025 shares of the biotechnology company’s stock after selling 7,011 shares during the period. Rice Hall James & Associates LLC’s holdings in ADMA Biologics were worth $7,049,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Vontobel Holding Ltd. grew its stake in shares of ADMA Biologics by 7.0% in the third quarter. Vontobel Holding Ltd. now owns 13,643 shares of the biotechnology company’s stock worth $273,000 after acquiring an additional 888 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after acquiring an additional 967 shares during the last quarter. State of Alaska Department of Revenue grew its stake in shares of ADMA Biologics by 1.0% in the fourth quarter. State of Alaska Department of Revenue now owns 134,346 shares of the biotechnology company’s stock worth $2,304,000 after acquiring an additional 1,337 shares during the last quarter. Hollencrest Capital Management bought a new position in ADMA Biologics in the third quarter worth $30,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in ADMA Biologics by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,430 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 1,509 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

ADMA has been the subject of several research reports. HC Wainwright raised their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, November 8th. Raymond James raised their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 3.70% of the company’s stock.

ADMA Biologics Stock Down 1.1 %

Shares of ADMA stock opened at $15.90 on Tuesday. The stock has a market cap of $3.76 billion, a P/E ratio of 56.79 and a beta of 0.75. The stock has a fifty day moving average price of $17.21 and a 200 day moving average price of $17.87. ADMA Biologics, Inc. has a one year low of $5.02 and a one year high of $23.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.